| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/22/2004 | US20040142872 Polyamine modified antibodies having specific binding affinity for A beta also have increased permeability at the blood-brain barrier and can be used for passive immunization and treatment of Altzheimer's disease |
| 07/22/2004 | US20040142870 N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
| 07/22/2004 | US20040142867 Stabilized proteinic preparation |
| 07/22/2004 | US20040142861 at least one genetically-engineered growth factor, at least one genetically-engineered antioxidant, at least one genetically-engineered extracellular matrix component |
| 07/22/2004 | US20040142475 Delivery systems for bioactive agents |
| 07/22/2004 | US20040142474 Liposomic structure comprising polyethylenimine (PEI), a fatty acid, cholesterol and polyethylene glycol for use as gene transfer tool in tissue engineering |
| 07/22/2004 | US20040142465 Injectable hyaluronic acid derivative with pharmaceuticals/cells |
| 07/22/2004 | US20040142451 one linker, a biomolecule coupled to the linker, and cyclohexane derivatives |
| 07/22/2004 | US20040142317 Use of amino acid transporter atbo,+ as a delivery system for drugs and prodrugs |
| 07/22/2004 | US20040142043 spray-dried fine powder comprising an active protein and a saccharide such as mannitol or cyclodextrin having a particle diameter of 10 mu m or less uniformly dispersed in the matrix of a biodegradable polymer |
| 07/22/2004 | US20040142041 alumina particles, silica particles or alumina coated particles as carrier having a functional compound adsorbed on the surface that is released when exposed to an environmental or chemical condition |
| 07/22/2004 | US20040142039 Solid and semi-solid polymeric ionic conjugates |
| 07/22/2004 | US20040142033 releases the following quantities of oxcarbazepine:15 min: 55 to 85%30 min: 75 to 95%45 min: 85 to 100%60 min: 90 to 100%in vitro |
| 07/22/2004 | US20040142031 carrier containing more than 10% by weight of a water-insoluble starch; shelf-life under relatively dry circumstances is enhanced. |
| 07/22/2004 | US20040142030 Stabilized tibolone compositions |
| 07/22/2004 | US20040142029 cellulose polymer, a methacrylic polymer and an active ingredient homogeniously distributed in a molecular state in an atomized matrix; also contains an organic base or an alkaline salt; and an adsorbent |
| 07/22/2004 | US20040142028 carrier containing more than 10% by weight of a water-insoluble starch; shelf-life under relatively dry circumstances is enhanced. |
| 07/22/2004 | US20040142027 vehicle comprising; a modified unsaturated oil and, optionally, a non-oxidizable oil; immediately after manufacture, composition can be administered such that the bioactive agents are released to the host on a predictable sustained basis. |
| 07/22/2004 | US20040142025 providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber; prepared rapidly at low pressure |
| 07/22/2004 | US20040142024 Patch formulation for external use |
| 07/22/2004 | US20040142023 rosin ester which provides a crystal inhibiting and drug stabilizing effect; capable of achieving zero-order kinetics for delivery of the active agent for a prolonged period of time |
| 07/22/2004 | US20040142022 exposure to electron beam radiation, preferably low level electron beam radiation, to produce sterilized patch for transdermal delivery |
| 07/22/2004 | US20040142000 Immune activator |
| 07/22/2004 | US20040141998 antigen is targeted to the receptor of the antigen-presenting cell, in some instances without being blocked by the natural ligand for the surface receptor; molecular complexes including the binding agent coupled to an antigen. |
| 07/22/2004 | US20040141982 Use of genetically engineered antibodies to treat multiple myeloma |
| 07/22/2004 | US20040141981 administering biological conjugates comprising chlorotoxin sensitive cytoplasmic proteins, used for the screening and prophylaxis of cancer |
| 07/22/2004 | US20040141967 Methods and compositions for treating macrophage-mediated diseases |
| 07/22/2004 | US20040141949 Treatment of mucositis |
| 07/22/2004 | US20040141945 novel material which combines cell-adhesive proteins such as collagen with GAG polymers to construct an environment similar to an extracellular matrix, capable of controlling differentiation and proliferation of cells |
| 07/22/2004 | US20040141944 polymer synthesized by a cross-coupling reaction of polymer scaffold units and xenoantigens |
| 07/22/2004 | US20040141937 Surfactant-containing cosmetic, dermatological and pharmaceutical agents |
| 07/22/2004 | US20040141932 Methods of use and of making a mascara comprising at least one coloring agent and at least one polyamide polymer chosen from ethylenediamine stearyl dimer tallate copolymer |
| 07/22/2004 | US20040141925 Nanoparticles; therapy of arthritis, skin disorders, blood disorders, kidney disorders, eye disorders, thyroid, intestinal disorders, cancer, allergic reactions, asthma, contact dermatitis, atopic dermatitis, seasonal allergic rhinitis |
| 07/22/2004 | US20040141922 Ultrasound contrast agents |
| 07/22/2004 | DE202004003404U1 Pharmazeutische Zusammensetzung zur kontrollierten Freisetzung von Wirkstoffen A pharmaceutical composition for controlled release of active ingredients |
| 07/22/2004 | CA2512735A1 Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| 07/22/2004 | CA2512513A1 Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| 07/22/2004 | CA2512138A1 Kim-1 antagonists and use to modulate immune system |
| 07/22/2004 | CA2512001A1 Complexes of protein crystals and ionic polymers |
| 07/22/2004 | CA2511966A1 Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| 07/22/2004 | CA2511820A1 Calcium phosphate ceramics and particles for in vivo and in vitro transfection |
| 07/22/2004 | CA2511815A1 Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| 07/22/2004 | CA2511814A1 Polymer conjugates of interferon-beta with enhanced biological potency |
| 07/22/2004 | CA2511540A1 Acid labile drug compositions |
| 07/22/2004 | CA2511512A1 Immunogenic compositions containing phospholipid |
| 07/22/2004 | CA2511486A1 Tissue reactive compounds and compositions and uses thereof |
| 07/22/2004 | CA2510903A1 Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| 07/22/2004 | CA2509248A1 Polymeric reagents comprising a ketone or a related functional group |
| 07/22/2004 | CA2509153A1 Hydrolytically stable maleimide-terminated polymers |
| 07/22/2004 | CA2508751A1 Polyamino acids functionalized by at least one (oligo)amino acid group and therapeutic uses |
| 07/21/2004 | EP1439199A1 Medical polymers and use thereof |
| 07/21/2004 | EP1438974A2 pH-sensitive liposomes based on diacyl-glycero-phosphoethanolamine and diacyl-succinyl-glycerol |
| 07/21/2004 | EP1438967A2 Pharmaceutical compositions of fibrinolytic agent |
| 07/21/2004 | EP1438959A1 Controlled release oxycodone compositions |
| 07/21/2004 | EP1438405A1 Use of a double-stranded ribonucleic acid for specifically inhibiting the expression of a given target gene |
| 07/21/2004 | EP1438340A2 Antibodies against kdr, their production and uses |
| 07/21/2004 | EP1438103A1 Betaine-containing cosmetics |
| 07/21/2004 | EP1438076A1 Radiopharmaceutical agent for the treatment of early stage cancer |
| 07/21/2004 | EP1438074A2 Adjuvant compositions |
| 07/21/2004 | EP1438073A2 Polyoxyalkylenes conjugates as enzyme inhibitors |
| 07/21/2004 | EP1438072A2 Polysaccharide-based network and method for the production thereof |
| 07/21/2004 | EP1438067A1 Autologous growth factor cocktail composition, method of production and use |
| 07/21/2004 | EP1438060A2 Prevention and treatment of restenosis by local administration of drug |
| 07/21/2004 | EP1438059A1 Composition containing horse chestnut extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 07/21/2004 | EP1438032A2 Production of starch-gel-based shaped bodies |
| 07/21/2004 | EP1438031A1 Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer |
| 07/21/2004 | EP1438030A2 Modified release dosage forms |
| 07/21/2004 | EP1438028A1 Modified release dosage forms |
| 07/21/2004 | EP1438027A1 Methods of treatment using a gastric retained losartan dosage |
| 07/21/2004 | EP1438026A2 Taste masking spill-resistant formulation |
| 07/21/2004 | EP1438024A1 Process for dispersing a fluid in solid particles |
| 07/21/2004 | EP1438022A1 Drug release system for controlled therapy |
| 07/21/2004 | EP1438021A2 Methods and apparatus for extrusion of vesicles at high pressure |
| 07/21/2004 | EP1438020A2 Topical compositions and methods for treating pain |
| 07/21/2004 | EP1438019A1 Kit for the preparation of a pharmaceutical composition |
| 07/21/2004 | EP1438018A1 Fondant-based pharmaceutical composition |
| 07/21/2004 | EP1437975A2 Optically-absorbing nanoparticles for enhanced tissue repair |
| 07/21/2004 | EP1404351A4 Carbohydrate modifying agent and drinks containing the modifying agent |
| 07/21/2004 | EP1357977B1 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
| 07/21/2004 | EP1331001B1 Novel dispersible and soluble galenic paracetamol formulation, method for its preparation and its applications |
| 07/21/2004 | EP1007009B1 A pharmaceutical composition having two coating layers |
| 07/21/2004 | EP0999843B1 Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use |
| 07/21/2004 | EP0966207B1 Composition comprising a liquid absorbed on a support based on precipitate silica |
| 07/21/2004 | EP0959904B1 Hybrid compositions for intracellular targeting |
| 07/21/2004 | EP0910353B1 Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents |
| 07/21/2004 | EP0635030B1 IMMUNOTOXINS DIRECTED AGAINST c-erbB-2 (HER-2/neu) RELATED SURFACE ANTIGENS |
| 07/21/2004 | CN1514868A Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
| 07/21/2004 | CN1514844A Modified granulocyte colony stimulating factor (G-CSF) with reduced immunogenicity |
| 07/21/2004 | CN1514839A 3,7-diazybicyclo [3.3.1] for mulations as antiarrhytmic compounds |
| 07/21/2004 | CN1514838A 3,7-diazybicyclo [3.3.1] for mulations as antiarrhytmic compounds |
| 07/21/2004 | CN1514736A Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers |
| 07/21/2004 | CN1514735A Ophthalmic composition comprising hyaluronic acid |
| 07/21/2004 | CN1514733A Modified erythropoietin (EPO) with reduced immunogenicity |
| 07/21/2004 | CN1514732A Pharmaceutical formulation consisting of plant extract with calcium coating |
| 07/21/2004 | CN1514729A Sustained-release analgesic compounds |
| 07/21/2004 | CN1514728A Nicotine-containing film preparation |
| 07/21/2004 | CN1514726A Pharmaceutical compositions |
| 07/21/2004 | CN1514725A Pharmaceutical composition comprising lipase inhibitor and sucrose fatty acid ester |
| 07/21/2004 | CN1514722A Controlled release dosage forms using acrylic polymer, and process for making |
| 07/21/2004 | CN1514720A Self emulsifying lipid matrix (SELM) |